Pfizer Clinches Deal for Obesity Drug Developer Metsea
Digest more
Pfizer not only beat expectations last quarter, but also boosted its guidance.
TipRanks on MSN
Is Pfizer (PFE) a Good Stock to Buy before Earnings?
Drugmaker Pfizer ($PFE) is set to report its Q3 earnings results on November 4 before the market opens. Analysts are ...
The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...
Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...
Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...
14don MSNOpinion
Should You Buy Pfizer Stock Before Nov. 4?
Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...
Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School ...
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback